ArticleAAPS PharmSciTech2014
Optimization of dexamethasone mixed nanomicellar formulation.
Article in AAPS PharmSciTech, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 54 citations in OpenAlex.
- Nanoencapsulated senotherapeutic compounds targeting connexin-43 for enhanced wound healing.iScience · 2026Article
- Development of a reverse-phase HPLC method for the simultaneous determination of curcumin and dexamethasone in polymeric micelles.Future science OA · 2025Article
- Selenium Nanoparticles: Synthesis, Stability and In Vitro Evaluation in Human Lens Epithelial Cells.Pharmaceutics · 2025Article
- Development of a peptide-based tumor-activated checkpoint inhibitor for cancer immunotherapy.Acta biomaterialia · 2025Article
- Novel fabrication of anti-VEGF drug ranibizumab loaded PLGA/PLA co-polymeric nanomicelles for long-acting intraocular delivery in the treatment of age-related macular degeneration therapy.Regenerative therapy · 2024Article
- Gene Therapy in the Anterior Eye Segment.Current gene therapy · 2022Review
- Improvement of Imiquimod Solubilization and Skin Retention via TPGS Micelles: Exploiting the Co-Solubilizing Effect of Oleic Acid.Pharmaceutics · 2021Article
- Combination of Nanomicellar Technology and In Situ Gelling Polymer as Ocular Drug Delivery System (ODDS) for Cyclosporine-A.Pharmaceutics · 2021Article
- Nanomicelles: Types, properties and applications in drug delivery.IET nanobiotechnology · 2021Review
- Enzyme-responsive polymeric micelles of cabazitaxel for prostate cancer targeted therapy.Acta biomaterialia · 2020Article
- Assembling Surfactants-Mucoadhesive Polymer Nanomicelles (ASMP-Nano) for Ocular Delivery of Cyclosporine-A.Pharmaceutics · 2020Article
- A Novel Gel-Forming Solution Based on PEG-DSPE/Solutol HS 15 Mixed Micelles and Gellan Gum for Ophthalmic Delivery of Curcumin.Molecules (Basel, Switzerland) · 2019Article
- Intravitreal anti-VEGF agents, oral glucocorticoids, and laser photocoagulation combination therapy for macular edema secondary to retinal vein occlusion: preliminary report.International journal of ophthalmology · 2018Article
- Recent Advances in the Application of Vitamin E TPGS for Drug Delivery.Theranostics · 2018Review
- Low density lipoprotein - rosiglitazone - chitosan-calcium alginate/nanoparticles inhibition of human tenon's fibroblasts activation and proliferation.Oncotarget · 2017Article
- Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies.Journal of controlled release : official journal of the Controlled Release Society · 2017Review
- Topical delivery of aqueous micellar resolvin E1 analog (RX-10045).International journal of pharmaceutics · 2016Article
- Nanomicellar Topical Aqueous Drop Formulation of Rapamycin for Back-of-the-Eye Delivery.AAPS PharmSciTech · 2015Article
- Topical, Aqueous, Clear Cyclosporine Formulation Design for Anterior and Posterior Ocular Delivery.Translational vision science & technology · 2015Article
- Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The purpose of this study was to develop a clear aqueous mixed nanomicellar formulation (MNF) of dexamethasone utilizing both D-α-tocopherol polyethylene glycol-1000 succinate (Vit E TPGS) and octoxynol-40 (Oc-40). In this study, Vit E TPGS and Oc-40 are independent variables. Formulations were prepared following solvent evaporation method. A three level full-factorial design was applied to optimize the formulation based on entrapment efficiency, size, and polydispersity index (PDI). A specific blend of Vit E TPGS and Oc-40 at a particular wt% ratio (4.5:2.0) produced excellent drug entrapment, loading, small mixed nanomicellar size and narrow PDI. Solubility of DEX in MNF is improved by ~6.3-fold relative to normal aqueous solubility. Critical micellar concentration (CMC) for blend of polymers (4.5:2.0) was found to be lower (0.012 wt%) than the individual polymers (Vit E TPGS (0.025 wt%) and Oc-40 (0.107 wt%)). No significant effect on mixed nanomicellar size and PDI with one-factor or multi-factor interactions was observed. Qualitative (1)H NMR studies confirmed absence of free drug in the outer aqueous MNF medium. MNF appeared to be highly stable. Cytotoxicity studies on rabbit primary corneal epithelial cells did not indicate any toxicity suggesting MNF of dexamethasone is safe and suitable for human topical ocular drops after further in vivo evaluations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.